358 South Main Street
LabCorp is a leading global life sciences company. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care.
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories.
With scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, LabCorp processes tests on approximately 500,000 specimens each day, applying advances in medicine and science to laboratory testing.
LabCorp operates a sophisticated laboratory network, with corporate headquarters in Burlington, NC, and more than 50,000 employees worldwide. Our 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. Laboratory Corporation of America Holdings is listed on the New York Stock Exchange (NYSE) under ticker symbol LH.
53 articles with LabCorp
LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer
LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the availability of a newly-approved companion diagnostic by the U.S. Food and Drug Administration (FDA), the therascreen® FGFR mutation assay by RGQ RT-PCR,
KIYATEC Announces $3 Million Initial Closing of Series B2 Preferred Stock Financing and New Investor LabCorp
The round was led by VentureSouth and included LabCorp®
Q1 revenue of $2.79 billion, down 2% from $2.85 billion last year
LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider
LabCorp will purchase Envigo’s nonclinical contract research services business, expanding the global reach and capabilities of Covance’s nonclinical drug development business
Interested parties can access the conference call by dialing 844-634-1444 within the U.S. and Canada, or 1-615-247-0253 internationally, using the passcode 7459328.
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 - April 1, 2019
LabCorp® announced that its Zero Coupon Convertible Subordinated Notes due 2021 may be converted as set forth below.
South San Francisco-based Mission Bio, the only company providing single-cell DNA sequencing, entered into a collaboration with LabCorp, to harness the abilities of the company’s Tapestri Platform to provide more precise clinical trials.
LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 17th Annual Scorecard on LGBTQ Workplace Equality
Receives Designation as a Best Place to Work for LGBTQ Equality for Second Year in a Row
LabCorp® announced that for the period of March 11, 2019 to Sept. 10, 2019, its Zero Coupon Convertible Subordinated Notes due 2021 will accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 6, 2019, in addition to the continued accrual of the original issue discount.
LabCorp® announced it will participate at the 2019 Barclays Global Healthcare Conference.
LabCorp Strengthens Leadership Position in Precision Medicine with Expansion of Therapeutic Drug Monitoring Portfolio
LabCorp’s DoseASSURE® Portfolio Provides Most Expansive Biologics TDM Menu Combined with Expert Guidance
LabCorp® announced results for the fourth quarter and year ended Dec. 31, 2018, and provided 2019 guidance.
LabCorp Named to FORTUNE Magazine's 2019 List of ‘World’s Most Admired Companies,’ Making the Annual List for the Second Consecutive Year
LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine's 2019 List of World’s Most Admired Companies, making the annual list for the second consecutive year.
The earnings release and accompanying financial information will be posted on the LabCorp Investor Relations website.
Conversion Right Triggered For LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 Dated as of October 24, 2006
LabCorp® announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.
GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)
Multi-Biomarker Test Will Provide the Clinical Research Community with a Non-Invasive Tool to Identify and Monitor Patients with NASH and Significant Fibrosis
LabCorp® today announced it will participate at the 37th Annual J.P. Morgan Healthcare Conference. LabCorp’s presentation is scheduled for Tuesday, January 8, 2019 at 1:30 p.m. (PT), followed by a question and answer session at 2:00 p.m. (PT).
Data-sharing results in an improved method of HER2 protein analysis which promises more accurate breast cancer diagnosis results.
Awarded CRO 2018 Customer Value Leadership Award
LabCorp® today updated its full-year 2018 guidance based on current expectations. In the following guidance, all comparisons to financial results in 2017 have been restated as if the Company had adopted the FASB-issued converged standard on revenue recognition (ASC 606) on January 1, 2017.